Impact of Age on Real-World Outcomes of Bispecific Antibodies in Patients with Relapsed Refractory DLBCL: CUBIC Consortium Analysis

Older patients with diffuse large B-cell lymphoma (DLBCL) have limited treatment options. Bispecific antibodies (BsAbs) are a novel immunotherapy with less acute toxicity compared to conventional therapies. This is a real-world analysis conducted to understand the safety and efficacy of BsAbs in older compared to younger patients. Adult patients with relapsed/refractory DLBCL who received commercially available BsAbs as a single agent between June 2023 and October 2025 across 10 U.S. centers in the CUBIC consortium were included. Key efficacy outcomes included response rates and survival; safety outcomes included cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). The analysis included 256 patients stratified by 3 age groups: <65 (71 patients), 65-74 (81 patients), ≥75 (104 patients). Median prior lines of therapy was 3, 80% were refractory to most recent therapy, and 40% would have been considered pivotal trial ineligible. At median follow-up of 9 months, the 12-month progression-free survival (PFS) was 30% and 12-month overall survival (OS) was 45%. Grade ≥3 CRS occurred in 5% patients; ICANS grade ≥3 occurred in 2% patients. There was no statistically significant difference in outcomes between the 3 age cohorts <65, 65-74, ≥75 with 12-month PFS 21%, 26%, 38%; 12-month OS 35%, 42%, 49%; grade ≥3 CRS 6%, 5%, 4%; and grade ≥3 ICANS 3%, 2%, 1% respectively. On multivariable analysis, ECOG ≥2 and elevated LDH were associated with inferior PFS and OS. Our analysis demonstrates that BsAbs maintain comparable efficacy and safety across all age groups, including patients ≥75 years.

Authors

Institutions

Publication Details

Journal
Blood Advances
Published
2026-11-18
DOI
https://doi.org/10.1182/bloodadvances.2026021461
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Impact of Age on Real-World Outcomes of Bispecific Antibodies in Patients with Relapsed Refractory DLBCL: CUBIC Consortium Analysis

Andrew Philip Jallouk, Mehdi Hamadani, Geoffrey Shouse, Yazeed Sawalha et al.
7 links
Blood Advances
Lymphoma Diagnosis and Treatment
article

Impact of Age on Real-World Outcomes of Bispecific Antibodies in Patients with Relapsed Refractory DLBCL: CUBIC Consortium Analysis

Andrew Philip Jallouk, Mehdi Hamadani, Geoffrey Shouse, Yazeed Sawalha, Gulrayz Ahmed, Alex Francisco Herrera, Shakthi Bhaskar, Sairah Ahmed, Allison Marie Bock, Pallawi Torka, Amy A. Ayers, Reid W. Merryman, Ajay Major, Lü Chen, Christopher R. Flowers, Ayushi Chauhan, Narendranath Epperla, Jennifer Leigh Crombie, Matthew Alexander Lunning, Lorenzo Falchi, Swetha Kambhampati Thiruvengadam, Jomel Meeko Manzano, Alexey V Danilov
article en

Abstract

Older patients with diffuse large B-cell lymphoma (DLBCL) have limited treatment options. Bispecific antibodies (BsAbs) are a novel immunotherapy with less acute toxicity compared to conventional therapies. This is a real-world analysis conducted to understand the safety and efficacy of BsAbs in older compared to younger patients. Adult patients with relapsed/refractory DLBCL who received commercially available BsAbs as a single agent between June 2023 and October 2025 across 10 U.S. centers in the CUBIC consortium were included. Key efficacy outcomes included response rates and survival; safety outcomes included cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). The analysis included 256 patients stratified by 3 age groups: <65 (71 patients), 65-74 (81 patients), ≥75 (104 patients). Median prior lines of therapy was 3, 80% were refractory to most recent therapy, and 40% would have been considered pivotal trial ineligible. At median follow-up of 9 months, the 12-month progression-free survival (PFS) was 30% and 12-month overall survival (OS) was 45%. Grade ≥3 CRS occurred in 5% patients; ICANS grade ≥3 occurred in 2% patients. There was no statistically significant difference in outcomes between the 3 age cohorts <65, 65-74, ≥75 with 12-month PFS 21%, 26%, 38%; 12-month OS 35%, 42%, 49%; grade ≥3 CRS 6%, 5%, 4%; and grade ≥3 ICANS 3%, 2%, 1% respectively. On multivariable analysis, ECOG ≥2 and elevated LDH were associated with inferior PFS and OS. Our analysis demonstrates that BsAbs maintain comparable efficacy and safety across all age groups, including patients ≥75 years.

Blood Advances
City Of Hope National Medical Center (US), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), Medical College of Wisconsin (US), Huntsman Cancer Institute (US), City of Hope (US), Dana-Farber Cancer Institute (US), Fred and Pamela Buffett Cancer Center (US), University of Colorado Anschutz Medical Campus (US), The Ohio State University (US), University of Nebraska Medical Center (US), Vanderbilt University Medical Center (US)
Good health and well-being
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon